z-logo
open-access-imgOpen Access
Ketamine Suppresses Proinflammatory Cytokine Production in Human Whole Blood In Vitro
Author(s) -
Takashi Kawasaki,
Masao Ogata,
Chika Kawasaki,
Junichi Ogata,
Yūta Inoue,
Akio Shigematsu
Publication year - 1999
Publication title -
anesthesia and analgesia/anesthesia and analgesia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.404
H-Index - 201
eISSN - 1526-7598
pISSN - 0003-2999
DOI - 10.1097/00000539-199909000-00024
Subject(s) - proinflammatory cytokine , tumor necrosis factor alpha , cytokine , medicine , lipopolysaccharide , ketamine , whole blood , immunology , interleukin , pharmacology , inflammation , anesthesia
The production of proinflammatory cytokines, such as tumor necrosis factor (TNF) a, interleukin (IL)-6, and IL-8, increases in patients with sepsis; marked production causes organ failure and septic shock. We previously reported that ketamine suppressed lipopolysaccharide (LPS)-induced TNF-alpha production in mice. However, there are no reports on the effect of ketamine on cytokine production in human whole blood. Therefore, in this study, we investigated the efficacy of ketamine on LPS-induced TNF-alpha, IL-6, and IL-8 production and recombinant human (rh) TNF-a-induced IL-6 and IL-8 production in human whole blood. After adding different doses of ketamine to whole blood, the blood was stimulated with LPS or rhTNF. After incubation, the plasma TNF-alpha activity and IL-6 and IL-8 concentrations were measured using the L929 cell cytotoxic assay or an enzyme-linked immunoassay. Ketamine significantly suppressed LPS-induced TNF-alpha production at concentrations >20 microg/mL. At concentrations >100 microg/mL, ketamine also significantly suppressed both LPS-induced and rhTNF-induced IL-6 and IL-8 production. In this study, we demonstrated that ketamine directly inhibits the production of proinflammatory cytokines such as TNF-alpha, IL-6, and IL-8 in human whole blood.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here